AtriCure (NASDAQ:ATRC) Receives Buy Rating from BTIG Research

BTIG Research restated their buy rating on shares of AtriCure (NASDAQ:ATRC) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $54.00 price target on the medical device company’s stock.

A number of other brokerages have also weighed in on ATRC. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, January 21st. JPMorgan Chase & Co. cut shares of AtriCure from an “overweight” rating to a “neutral” rating and set a $36.00 price target on the stock. in a report on Wednesday, February 11th. Oppenheimer downgraded shares of AtriCure from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $45.00 target price on shares of AtriCure in a research report on Thursday, February 12th. Finally, Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, AtriCure has an average rating of “Moderate Buy” and a consensus target price of $48.43.

AtriCure Price Performance

Shares of AtriCure stock opened at $32.26 on Wednesday. The company’s fifty day simple moving average is $38.59 and its two-hundred day simple moving average is $36.77. AtriCure has a 12-month low of $28.29 and a 12-month high of $43.18. The firm has a market cap of $1.60 billion, a PE ratio of -134.42 and a beta of 1.41. The company has a quick ratio of 2.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.15.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Tuesday, February 17th. The medical device company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. AtriCure had a negative net margin of 2.14% and a negative return on equity of 1.17%. The company had revenue of $140.50 million during the quarter, compared to analyst estimates of $140.50 million. During the same period in the prior year, the business posted ($0.33) earnings per share. AtriCure’s revenue for the quarter was up 13.1% on a year-over-year basis. As a group, equities analysts expect that AtriCure will post -0.6 EPS for the current year.

Insiders Place Their Bets

In related news, insider Justin J. Noznesky sold 5,166 shares of the firm’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $37.29, for a total transaction of $192,640.14. Following the completion of the transaction, the insider owned 78,798 shares of the company’s stock, valued at $2,938,377.42. This trade represents a 6.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sven Wehrwein sold 4,967 shares of AtriCure stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $38.00, for a total value of $188,746.00. Following the transaction, the director owned 34,374 shares of the company’s stock, valued at $1,306,212. The trade was a 12.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 18,166 shares of company stock worth $676,378. 3.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AtriCure

Large investors have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd increased its stake in AtriCure by 197.1% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 538 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of AtriCure during the second quarter valued at approximately $37,000. Farther Finance Advisors LLC increased its position in shares of AtriCure by 1,818.6% during the third quarter. Farther Finance Advisors LLC now owns 1,132 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 1,073 shares in the last quarter. First Horizon Corp bought a new stake in shares of AtriCure during the third quarter valued at approximately $42,000. Finally, Smartleaf Asset Management LLC raised its holdings in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after acquiring an additional 429 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure News Summary

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure reported Q4 2025 results that beat expectations: $0.06 EPS (vs. estimates for a loss) and $140.5M revenue, +13% year-over-year, and management signaled strong execution and forward momentum — a key fundamental reason for upside interest. AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
• Positive Sentiment: BTIG and other analysts reiterated Buy ratings and maintained ~ $54 price targets, citing sustained outperformance and manageable competition — analyst support can underpin shares going forward. AtriCure: Sustained Outperformance…54 Target
• Neutral Sentiment: Multiple earnings call transcripts and recaps are available (detailed commentary from management and analysts), which investors should read for guidance detail and margin/volume drivers. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Trading volume is well above average on the earnings day, indicating active repositioning; short-interest data reported appears anomalous and should be treated with caution. ATRC Tops Q4 Earnings
• Negative Sentiment: Citizens JMP cut its price target from $60 to $52 (still a market outperform), a modest downward revision that may temper some upside expectations and contributed to selling pressure. Benzinga: Price Target Change
• Negative Sentiment: Coverage noted rising competition in the Afib device space — a longer‑term risk that could pressure margins or market share if competitors gain traction. AtriCure posts Q4 beats on 13% growth, analysts label it ‘undervalued’ despite rising competition

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.